Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides
DermatologyInvestigational

SNAP-8 (Acetyl Octapeptide-3)

Topical
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

SNAP-8 is an elongated derivative of Argireline, consisting of eight amino acids (Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2) designed to further inhibit SNARE complex formation and catecholamine-mediated neurotransmitter release. By extending the peptide sequence, the molecule is hypothesized to achieve enhanced binding and greater reduction in muscle contraction intensity in facial expression zones.

Mechanism of Action

Like its hexapeptide predecessor, it is positioned as a non-invasive topical anti-wrinkle agent.

Research Summary & Key Findings

In vitro assays have demonstrated that acetyl octapeptide-3 can reduce neurotransmitter release in cell-free models at higher potency than acetyl hexapeptide-8. Manufacturer-sponsored clinical studies have reported wrinkle depth reductions of approximately 60 percent in some participants after 28 days, though independent peer-reviewed replication is absent. Standardized efficacy benchmarks and head-to-head comparisons with established treatments have not been published.

Clinical Status

Investigational

SNAP-8 (Acetyl Octapeptide-3) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Topical

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Dermatology

No lawful pathway today

SNAP-8 (Acetyl Octapeptide-3) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.

Tell me if the status changes

One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.